Table 1. Univariate and multivariate analyses of OS among patients with PDAC.
|
Survival |
Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| Prognostic factors | No. of patients | Median (months) | 2-year (%) | P-value | HR (95% CI) | P-value |
|
Age | ||||||
| <Median (69) | 52 | 20.6 | 49 | |||
| ⩾Median | 53 | 18.9 | 51 | 0.62 | ||
|
Gender | ||||||
| Male | 55 | 19.4 | 43 | |||
| Female | 50 | 20 | 58 | 0.09 | ||
|
Pathological differentiation | ||||||
| Well/moderate | 86 | 20.1 | 52 | |||
| Poorly | 19 | 14.3 | 40 | 0.45 | ||
|
UICC pT factor | ||||||
| T1/T2 | 3 | 46.8 | 100 | |||
| T3/T4 | 102 | 19.4 | 49 | 0.08 | ||
|
Lymph node metastasis | ||||||
| No | 29 | 38.3 | 40 | |||
| Yes | 76 | 16.6 | 78 | <0.001 | 2.2 (1.1–4.2) | 0.023 |
|
UICC final stage | ||||||
| IA/IB/IIA/IIB | 84 | 22.6 | 60 | |||
| III/IV | 21 | 14.1 | 14.3 | <0.001 | 2.0 (1.1–3.5) | 0.016 |
|
Residual tumour | ||||||
| R0 | 46 | 24.5 | 57 | |||
| R1 | 59 | 12.5 | 37 | 0.07 | ||
|
KRAS status of primary tumour | ||||||
| Wild-type | 19 | 31 | 72 | |||
| Mutant | 86 | 18.4 | 46 | 0.18 | ||
|
Pre-operative CEA value | ||||||
| <5.0 ng ml−1 | 74 | 21.5 | 47 | |||
| ⩾5.0 ng ml−1 | 31 | 14.5 | 32 | 0.14 | ||
|
Pre-operative CA19-9 value | ||||||
| <90 U ml−1 | 44 | 25 | 57 | |||
| ⩾90 U ml−1 | 61 | 19.4 | 41 | 0.023 | 1.2 (0.7–2.0) | 0.57 |
|
Presence of ctDNA | ||||||
| Negative | 72 | 27.6 | 53 | |||
| Positive | 33 | 13.6 | 21 | <0.0001 | 3.2 (1.8–5.4) | <0.001 |
Abbreviations: CA19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; CI=confidence interval; ctDNA=circulating tumour DNA; HR=hazard ratio; KRAS=v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog; OS=overall survival; PDAC=pancreatic ductal adenocarcinoma; UICC=Union for International Cancer Control.